This suggests that patients with high expression of glucose metabolism-related genes in ccRCC may be responsive to immune checkpoint inhibitors and that PD-1 therapy holds promise for development in these patients. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.